Drugs in Dev. Trauma (Emergency, Injury, Surgery)
Preclinical
Denmark 
Lead Product(s) : BP-C2
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Meabco's Drug Candidate Efficiently Mitigates Radiation-Induced Gastrointestinal Syndrome in Mice
Details : BP-C2 reduces mortality when administered 24 hours post-exposure in a murine model of severe, radiation-induced gastrointestinal acute radiation syndrome (GI-ARS).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : BP-C2
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BP-C2
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : $5.9 million
Deal Type : Funding
Details : This three-year contract consists of a one-year base period with two one-year optional periods that will allow Meabco to complete IND-enabling studies and advance BP-C2 as a therapy for treating the effects of unintentional radiation exposure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 25, 2020
Lead Product(s) : BP-C2
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : $5.9 million
Deal Type : Funding
Reset All
